Experts recommend screening adults for hypertriglyceridemia every five years

The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of hypertriglyceridemia. Triglycerides are a type of fat found in the blood and are associated with cardiovascular risk. The CPG, entitled "Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline" appears in the September 2012 issue of the Journal of Clinical Endocrinology and Metabolism (JCEM), a publication of The Endocrine Society.

The most common reasons for high triglycerides include being overweight, lack of exercise, the metabolic syndrome, , and familial combined hyperlipidemia, a genetic disorder that runs in the family. It results in high triglycerides, high "bad" (low-density lipoprotein, or LDL) cholesterol and low "good" (high-density lipoprotein, or HDL) cholesterol.

"There is increasing evidence that high triglyceride levels represent a and in addition, very high triglyceride level is a risk factor for pancreatitis," said Lars Berglund, MD, PhD, of the University of California, Davis, and chair of the task force that authored the guideline. "The guideline presents recommendations for diagnosis of high triglyceride levels, and recommendations for management and treatment."

Recommendations from the CPG include:

  • Because severe hypertriglyceridemia increases the risk for pancreatitis and mild hypertriglyceridemia may be a risk factor for cardiovascular disease, adults should be screened for hypertriglyceridemia as part of a lipid panel at least every five years;
  • Diagnosis of hypertriglyceridemia should be based on fasting triglyceride levels and not on non-fasting ;
  • Individuals found to have any elevation of fasting triglycerides should be evaluated for secondary causes of hyperlipidemia including endocrine conditions and medications. Treatment should be focused on such secondary causes;
  • Patients with primary hypertriglyceridemia should be assessed for other cardiovascular , such as central obesity, hypertension, abnormalities of glucose metabolism, and liver dysfunction;
  • Clinicians should evaluate patients with primary hypertriglyceridemia for family history of dyslipidemia and cardiovascular disease to assess genetic causes and future cardiovascular risk; and
  • Initial treatment of mild-to-moderate hypertriglyceridemia should be lifestyle therapy, including dietary counseling to achieve appropriate diet compostion, physical activity, and a program to achieve weight reduction in overweight and obese individuals.
The Hormone Health Network has published a companion patient guide to this CPG. The patient guide, which can be found online at http://www.hormone.org/Resources/upload/PG-Hypertriglyceridemia-web.pdf, explains how hypertriglyceridemia impacts the body and discusses treatment options.

add to favorites email to friend print save as pdf

Related Stories

Study sheds light on triglyceride metabolism

Jul 07, 2010

New findings reported in the July issue of Cell Metabolism are offering new leads as to why some people might suffer from high levels of triglycerides. High triglycerides are a risk factor for atherosclerosis and cardiovascular diseas ...

Recommended for you

Doctor behind 'free radical' aging theory dies

23 hours ago

Dr. Denham Harman, a renowned scientist who developed the most widely accepted theory on aging that's now used to study cancer, Alzheimer's disease and other illnesses, has died in Nebraska at age 98.

Mexican boy who had massive tumor recovering

Nov 25, 2014

An 11-year-old Mexican boy who had pieces of a massive tumor removed and who drew international attention after U.S. officials helped him get treatment in the southwestern U.S. state of New Mexico is still recovering after ...

New medical device to make the mines safer

Nov 21, 2014

Dehydration can be a serious health issue for Australia's mining industry, but a new product to be developed with input from Flinders University's Medical Device Partnering Program (MDPP) is set to more effectively ...

US family gets $6.75 million in Botox case

Nov 20, 2014

A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.